Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 50, Issue 4, 2006, Pages 288-295

  Cremonesi, M ^a   Ferrari, M ^a   Bodei, L ^a   Tosi, G ^a   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Peptides; Radiolabelling; Receptors

Indexed keywords

ANGIOPEPTIN; ANGIOPEPTIN IN 111; ANGIOPEPTIN Y 90; DOTATATE IN 111; DOTATATE LU 177; DOTATATE Y 90; DOTATOC IN 111; DOTATOC Y 86; DOTATOC Y 90; INDIUM 111; LUTETIUM 177; MONOCLONAL ANTIBODY; PENTETIC ACID; PENTETREOTIDE IN 111; PEPTIDE; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN DERIVATIVE; TENASCIN; UNCLASSIFIED DRUG; YTTRIUM 86; YTTRIUM 90;

BONE MARROW TOXICITY; BRACHYTHERAPY; BRAIN TUMOR; CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; GLIOBLASTOMA; GLIOMA; HUMAN; INFORMATION PROCESSING; ISOTOPE LABELING; LOCAL THERAPY; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; TESTOSTERONE BLOOD LEVEL;

BODY BURDEN; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRALESIONAL; NEOPLASMS; ORGAN SPECIFICITY; PEPTIDES; RADIATION DOSAGE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RECEPTORS, PEPTIDE;

EID: 33846491797     PISSN: 11250135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine. New York; 1988
2. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:375-61S.
3. Foster D, Barret P. Developing and testing integrated multicompartment models to describe a single- input multiple-output study using the SAAM II software system. In: Proc. Sixth International Radiopharmaceutical. Dosimetry Symposium, Oak Ridge Institute for Science and Education; 1998.
4. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37: 538-46.
5. RADAR (RAdiation Dose Assessment Resource). Stabin M, Siegel J, Lipsztein J, Hunt J, Brill A, Sparks R et al. www.doseinforadar.com; www.ieo.it/radar.
6. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294-310.
7. 90Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 2003;18:99-107.
8. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
9. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
10. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
11. 111)In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743-50.
12. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S-98S.
13. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-7.
14. Forrer F, Mueller-Brand J, MaeckeH. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2005;32:511-2.
15. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928-36.
16. 90Y-DOTATOC. Eur J Nucl Med 1999;26:877-86.
17. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12: 941-5.
18. 3]octreotate in patients with endocrine gastroentero-pancreatic tumors. J Clin Oncol 2005:23:2754-62.
19. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
20. 0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406-11.
21. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386-92.
22. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1257-62.
23. 3]octreotate: com- parison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
24. Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med 1997;38:1919-22.
25. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
26. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S-17S.
27. Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. J Nucl Med 2001;42:492-8.
28. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
29. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 2002;17:445-64.
30. Forssell-Aronsson E, Fjalling M, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-l-octreotide. J Nucl Med 1995;36:7-12.
31. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer 2004;90:1469-73.
32. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001;16:227-35.
33. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33.
34. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmutherapy approach. Eur J Nucl Med 2000;27:601-9.
35. 90Y-labelled radiopeptides. Eur J Nucl Med Mol Imaging 2002;29:1697-8.
36. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995;34:121-34.
37. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999;154:1345-52.
38. 3-octreotide (DOTATOC). Swiss Med Wkly 2001;131:640-4.
39. Hopkins K, Papanastassiou V, Zananiri FA, Kemshead JT. A model to estimate the dose to tumor following intracavity administration of radioimmunoconjugates to patients with malignant gliomas. Br J Radiol 1997;70:1152-61.
40. 90Y-DOTATOC. J Nucl Med 2006;47:105-12.
41. Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl 2003;88:83-91.
42. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SWJ. Coincidence of EGF receptor and somatostatin receptors in meningiomas but inverse, differentiation dependent relationship in glial tumors. Am J Phatol 1989;134:337-44.
43. Dale R. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1187-84.
44. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19:363-70.
45. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:45-12S.
46. 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001; 37:847-51.
47. 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2002;29:435.
48. 166Ho-DOTMP. Cancer Biother Radiopharm 2003;18:225-30.
49. Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA et al. Renal toxicity after radionuclide therapy. Radiat Res 2004;161:607-11.
50. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113-47.
51. Green A, Flynn A, Pedley RB, Dearling J, Begent R. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. Cancer Biother Radiopharm 2004;19:371-7.
52. 90'Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S-106S.
53. Perez A, Brady LW. Principles and practice of radiation oncology. Philadelphia: Lippincott-Raven Publishers; 1997.
54. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
55. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 2004;19:378-87.
56. de Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45:1168-71.
57. Breitz H. Clinical aspects of radiation nephropathy. Cancer Biother Radiopharm 2004;19:359-62.
58. Thames HD, Ang KK, Stewart FA, van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol 1988;54:13-9.
59. Barone R, De Camps J, Smith C, Kvols L, Krenning EP, Pauwels S et al. Amino acid (AA) solutions infused for renal radioprotection: metabolic effects. Nucl Med Commun 2000;21: